Summary
Overview
Work History
Education
Skills
Timeline
Generic

Elise T. Renkonen

Florida,USA

Summary

Global executive with over 18 years of leadership experience across pharmaceuticals, diagnostics, and precision medicine. Demonstrated success in driving end-to-end product and portfolio strategy from early pipeline through commercialization, and lifecycle optimization. Expert in shaping integrated global product strategies, executing successful go-to-market plans, and launching more than 20 diagnostic and therapeutic products in highly competitive markets. Adept at leading cross-functional global teams, optimizing resource allocation, and navigating complex regulatory and payer environments. Known for deep customer focus, market access, and evidence generation acumen. Proven ability to build high-performing organizations, align diverse stakeholders, and deliver sustained growth.

Overview

22
22
years of professional experience

Work History

Enterprise Business Leader, Product Strategy and Management

Roche Group: Foundation Medicine (FMI)
Boston, USA
12.2023 - Current
  • Own the end-to-end product lifecycle strategy and execution across FMI's clinical portfolio, from concept, development, and evidence generation, through launch, market adoption, and lifecycle optimization.
  • Lead two cross-functional Enterprise Business Teams (EBTs = LCTs) spanning R&D, tech, regulatory, access, commercial, and operations, driving the successful launch of multiple therapy selection (NGS, CGP) and response monitoring (ctDNA detection) LDTs, complex biomarkers, IHC markers, and CDx products.
  • Defined and executed a 5-year innovation roadmap and portfolio strategy, setting short-, mid-, and long-term priorities for product development and positioning. Secured organizational and executive leadership alignment.
  • Developed and operationalized an Integrated (medical, clinical and commercial) Launch Readiness Review (LRR) process, overseeing the go-to-market strategy, value proposition, launch planning, sales training, and customer engagement, driving rapid adoption and revenue growth.
  • Managed full portfolio financial performance, including annual and long-range forecasts, budget and resource allocation, and revenue tracking.
  • Optimized operating models within a rapidly scaling organization, driving resource efficiencies, and engagement.
  • Commercial lead in developing corporate market expansion strategies for rare diseases, neurology, and cardiology.
  • Analyzed market trends and engaged with KOLs to inform strategic decision-making processes.

Enterprise Business Leader, Monitoring Portfolio

Roche Group: Foundation Medicine (FMI)
10.2022 - 12.2023
  • Achieved corporate objectives and key results in 2022, 2023, and 2024, including multiple product launches to the BioPharma and clinical markets globally, driving double-digit month-over-month post-launch growth.
  • Piloted and implemented a new business stage-gate process, and coached the team to obtain FMI's first stage-gate exit approval. Recognized for creating multiple best practices, such as a decision factor framework to guide strategic decision-making, and a new project resource estimation and prioritization matrix.
  • Coached direct reports and cross-functional stakeholders through organizational transformation, the formation of an enterprise business team model by designing training and workshops to enhance the team's capabilities to meet new roles, business, and organizational requirements.

Lifecycle Leader, Monitoring Portfolio, Global Portfolio Strategy

Roche Group: Foundation Medicine (FMI)
08.2020 - 10.2022
  • Designed and executed FMI's first Monitoring Portfolio Strategy, including risk management frameworks to guide product development and commercialization priorities.
  • Led lifecycle development and market entry of F1Tracker, securing FDA Breakthrough Device Designation, New York State approval, and broad Medicare coverage.
  • Oversaw the integration of the acquired company's pipeline, steering product consolidation and portfolio decision-making to optimize commercialization potential.
  • Collaborated with the C-Suite to refine FMI's lifecycle model, operating principles, and resource allocation processes.

Lung and Pan Tumor Franchise Sales Leader, Southeast

Roche Group: Genentech Inc.
South San Francisco, USA
04.2018 - 08.2020
  • Elevated FL and GA divisions to US top three by developing clinical sales specialists.
  • Mobilized a cross-functional team for the first U.S. commercial sale, driving rapid biomarker testing adoption.
  • Achieved a successful launch of Rozlytrek and increased Alecensa's market share amid competition.
  • Delivered substantial sales growth by enhancing non-clinical selling capabilities within the team.
  • Coached the sales team through three Tecentriq launches and label extensions to maximize impact.

Lifecycle Leader, TECENTRIQ, Oncology

Roche Group: Genentech Inc.
South San Francisco, USA
01.2018 - 04.2018
  • Maximized cancer immunotherapy portfolio value by leading two cross-functional lifecycle teams (hematology and breast and gynecologic tumors) through the annual lifecycle planning and governance process.
  • Effectively led the LCT through a complex issue management situation, where HTA (FDA, EMA) feedback and an unexpected termination of a planned external collaboration significantly impacted the value of the Multiple Myeloma development plan. Obtained senior management's approval for a mitigation strategy to avoid $0.5 billion extra cost.
  • Supported senior management with business review and investor relations meeting preparations, and led partnership negotiations at the JP Morgan conference.

International Business Leader, TECENTRIQ, Solid tumors and Heme

Roche Group: Genentech Inc.
South San Francisco, USA
03.2015 - 03.2018
  • Led a high-performing Global Brand Team of 11 global cross-functional leaders and an International Business team of 8, defining a shared vision, objectives, commercialization, and marketing strategy.
  • Hired and coached three International Product Managers (IPMs), overseeing the development of the global brand strategies, the execution of global tactical plans, and ensuring effective local implementation.
  • Developed TECENTRIQ's disease area strategies in breast and gynecological cancers, resulting in the initiation of three ovarian and five breast cancer Phase 3 trials and the company's ability to leapfrog ahead of competitors' launch timelines.
  • Secured 12 Business Review Committee approvals in oncology and infectious diseases, enabling therapeutic area leadership by identifying high-return investment opportunities.
  • Recognized by global leadership for unlocking TECENTRIQ's commercial value in TNBC through an innovative FDA and EMA filing and launch strategy, overcoming pricing and market access challenges.
  • Developed partnership and investment strategies, identifying eight first-in-class therapy combination opportunities.
  • Contributed to Pharma Leadership Team goals by leading deal evaluations for Foundation Medicine and FlatIron partnerships, and advancing the commercial use of clinic-genomic databases and real-world data (RWD/RWE).

International Business Leader, TASREIZO

Roche Group: Genentech Inc.
South San Francisco, USA
11.2014 - 03.2015
  • Led the global commercialization, development, and execution of the first PI3K-targeted therapy.
  • Aligned global, regional, LCT, and IBT countries on vision, strategy, launch readiness process, strategy, and execution.

International Product Manager, Avastin (antiangiogenic) Breast Cancer

Roche Group: Hoffman La Roche Pharmaceuticals
Basel, Switzerland
03.2013 - 10.2014
  • Exceeded business goals as ad interim Avastin IBL BC by aligning regional leadership and major markets behind a new strategic direction, and by motivating the team through three negative Phase 3 data readouts and negative media attention.
  • Developed marketing and tactical plans for global regions and affiliates, including customer segmentation, patient profiling, and competitive readiness training against in-class and out-of-class competitors.
  • In collaboration with Market Access team, designed and implemented global and local access plans.
  • Receiver of the GPS-PDMA Spirit Award for inspirational and motivational leadership.

International Product Manager, Avastin (antiangiogenic) Pan Tumor

Roche Group: Hoffman La Roche Pharmaceuticals
Basel, Switzerland
04.2012 - 10.2013
  • Led the global Avastin branding team (80+ members across 15 markets), driving the launch of new branding, positioning, tagline, and messaging.
  • Boosted morale and implementation through internal motivational campaigns.
  • Led the planning and execution of Global Implementation Meetings across 142 Roche affiliates worldwide.

Senior Product and Sales Manager, HER2 franchise (anti-HER2 antibodies and ADCs)

Roche Group: Roche Pharmaceuticals, Finland Oy.
Espoo, Finland
10.2010 - 04.2012
  • Built HER2 franchise launch readiness, brand and biosimilar readiness strategies and tactical execution plans.
  • Coached and developed National Herceptin sales representatives to overcome sales and access barriers in their territories, leading to +15% growth in 2011 over the target and a career promotion for one of the specialists.
  • Exceeded both quantitative and qualitative goals and awarded as Region Europe Top Performer.

Product and Sales Manager Xeloda, Medical Manager Xeloda (chemotherapy)

Roche Group: Roche Pharmaceuticals, Finland Oy.
Espoo, Finland
08.2007 - 10.2010
  • Built and coached a new national sales team to execute the adjuvant colon and gastric cancer launches.
  • Achieved highest growth rate in the EU (YOY +24% in 2009 vs YoY +9 % in 2010) in two consecutive years.
  • Medical Manager: led investigator meetings, advisory boards and served as a POC for the Global filing team.
  • Build and executed on-demand KOL advisory boards and nation-wide stakeholder and account management plans.

Ph.D. Researcher and Post Doc

Helsinki University, Faculty of Medicine
Helsinki, Finland
01.2004 - 01.2007
  • Developed a diagnostic cancer screening test resulting earlier detection, reduced morbidity, and mortality.
  • Multiplied impact at international scale by initiating academic collaborations in US, LATAM and EU.
  • Author of 7 peer-reviewed articles (e.g. JCO) with 250+ citations in academic publications.

Education

BBA - Bachelor of Business Administration And Marketing Excellence

Helsinki School of Economics
Helsinki, Finland
10-2010

Ph.D. - Medical Genetics

University of Helsinki
Helsinki, Finland
01.2007

Master of Science - Medical Genetics

University of Helsinki
Helsinki,Finland
01-2004

Skills

  • Corporate strategy and global market expansion
  • Product and portfolio lifecycle leadership
  • Go-to-market and launch excellence
  • Marketing strategy, branding, and execution
  • P&L management and forecasting
  • Market access, HEOR, and reimbursement
  • KOL engagement and voice of customer
  • Regulatory awareness and risk management
  • Organizational and cross-functional leadership
  • Talent development and succession planning

Timeline

Enterprise Business Leader, Product Strategy and Management

Roche Group: Foundation Medicine (FMI)
12.2023 - Current

Enterprise Business Leader, Monitoring Portfolio

Roche Group: Foundation Medicine (FMI)
10.2022 - 12.2023

Lifecycle Leader, Monitoring Portfolio, Global Portfolio Strategy

Roche Group: Foundation Medicine (FMI)
08.2020 - 10.2022

Lung and Pan Tumor Franchise Sales Leader, Southeast

Roche Group: Genentech Inc.
04.2018 - 08.2020

Lifecycle Leader, TECENTRIQ, Oncology

Roche Group: Genentech Inc.
01.2018 - 04.2018

International Business Leader, TECENTRIQ, Solid tumors and Heme

Roche Group: Genentech Inc.
03.2015 - 03.2018

International Business Leader, TASREIZO

Roche Group: Genentech Inc.
11.2014 - 03.2015

International Product Manager, Avastin (antiangiogenic) Breast Cancer

Roche Group: Hoffman La Roche Pharmaceuticals
03.2013 - 10.2014

International Product Manager, Avastin (antiangiogenic) Pan Tumor

Roche Group: Hoffman La Roche Pharmaceuticals
04.2012 - 10.2013

Senior Product and Sales Manager, HER2 franchise (anti-HER2 antibodies and ADCs)

Roche Group: Roche Pharmaceuticals, Finland Oy.
10.2010 - 04.2012

Product and Sales Manager Xeloda, Medical Manager Xeloda (chemotherapy)

Roche Group: Roche Pharmaceuticals, Finland Oy.
08.2007 - 10.2010

Ph.D. Researcher and Post Doc

Helsinki University, Faculty of Medicine
01.2004 - 01.2007

BBA - Bachelor of Business Administration And Marketing Excellence

Helsinki School of Economics

Ph.D. - Medical Genetics

University of Helsinki

Master of Science - Medical Genetics

University of Helsinki

Similar Profiles

CREATE PROFILE